Skip Nav Destination
Issues
1 October 2020
-
Cover Image
Cover Image
The cover shows a multiplex immunofluorescence (MIF) image of a nonresponder HNSCC patient with minimal CD8+ T-cell infiltrates in a baseline tumor biopsy. CD8+ T cell infiltrates at baseline correlated with neoadjuvant anti–PD1 pathologic response in surgically resectable, advanced HNSCC. For details, see article by Uppaluri et al. on page 5140 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
Special Report
CCR Translations
CCR Drug Updates
FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis
Shaily Arora; Sanjeeve Balasubramaniam; Wei Zhang; Lijun Zhang; Rajeshwari Sridhara; Dianne Spillman; Jaigi P. Mathai; Bradley Scott; Sarah J. Golding; Michael Coory; Richard Pazdur; Julia A. Beaver
Reviews
Clinical Trial Brief Report
Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B
Matteo S. Carlino; Alexander M. Menzies; Victoria Atkinson; Jonathan S. Cebon; Michael B. Jameson; Bernard M. Fitzharris; Catriona M. McNeil; Andrew G. Hill; Antoni Ribas; Michael B. Atkins; John A. Thompson; Wen-Jen Hwu; F. Stephen Hodi; Alexander D. Guminski; Richard Kefford; Haiyan Wu; Nageatte Ibrahim; Blanca Homet Moreno; Georgina V. Long
Clinical Trials: Targeted Therapy
A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer
Michael J. Pishvaian; Hongkun Wang; Aiwu Ruth He; Jimmy J. Hwang; Brandon G. Smaglo; Sunnie S. Kim; Benjamin A. Weinberg; Louis M. Weiner; John L. Marshall; Jonathan R. Brody
Author Choice
A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K-mutant Solid Tumors
Ryan J. Sullivan; Jeffrey Weber; Sapna Patel; Reinhard Dummer; Matteo S. Carlino; Daniel S.W. Tan; Celeste Lebbé; Salvatore Siena; Elena Elez; Lance Wollenberg; Michael D. Pickard; Victor Sandor; Paolo A. Ascierto
Clinical Trials: Immunotherapy
Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275
Matthew D. Galsky; Abdel Saci; Peter M. Szabo; G. Celine Han; Gary Grossfeld; Sandra Collette; Arlene Siefker-Radtke; Andrea Necchi; Padmanee Sharma
A Phase II Study of Allogeneic GM-CSF–Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer
Annie A. Wu; Katherine M. Bever; Won Jin Ho; Elana J. Fertig; Nan Niu; Lei Zheng; Rose M. Parkinson; Jennifer N. Durham; Beth Onners; Anna K. Ferguson; Cara Wilt; Andrew H. Ko; Andrea Wang-Gillam; Daniel A. Laheru; Robert A. Anders; Elizabeth D. Thompson; Elizabeth A. Sugar; Elizabeth M. Jaffee; Dung T. Le
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
Ravindra Uppaluri; Katie M. Campbell; Ann Marie Egloff; Paul Zolkind; Zachary L. Skidmore; Brian Nussenbaum; Randal C. Paniello; Jason T. Rich; Ryan Jackson; Patrik Pipkorn; Loren S. Michel; Jessica Ley; Peter Oppelt; Gavin P. Dunn; Erica K. Barnell; Nicholas C. Spies; Tianxiang Lin; Tiantian Li; David T. Mulder; Youstina Hanna; Iulia Cirlan; Trevor J. Pugh; Tenny Mudianto; Rachel Riley; Liye Zhou; Vickie Y. Jo; Matthew D. Stachler; Glenn J. Hanna; Jason Kass; Robert Haddad; Jonathan D. Schoenfeld; Evisa Gjini; Ana Lako; Wade Thorstad; Hiram A. Gay; Mackenzie Daly; Scott J. Rodig; Ian S. Hagemann; Dorina Kallogjeri; Jay F. Piccirillo; Rebecca D. Chernock; Malachi Griffith; Obi L. Griffith; Douglas R. Adkins
Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study
Kevin J. Harrington; Anthony Kong; Nicolas Mach; Jason A. Chesney; Beatriz Castelo Fernandez; Danny Rischin; Ezra E.W. Cohen; Hoi-Shen Radcliffe; Burak Gumuscu; Jonathan Cheng; Wendy Snyder; Lillian L. Siu
Precision Medicine and Imaging
Author Choice
ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials
Nicholas C. Turner; Claire Swift; Lucy Kilburn; Charlotte Fribbens; Matthew Beaney; Isaac Garcia-Murillas; Aman U. Budzar; John F.R. Robertson; William Gradishar; Martine Piccart; Gaia Schiavon; Judith M. Bliss; Mitch Dowsett; Stephen R.D. Johnston; Stephen K. Chia
First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer
Mark P.S. Dunphy; Christina Pressl; Nagavarakishore Pillarsetty; Milan Grkovski; Shanu Modi; Komal Jhaveri; Larry Norton; Bradley J. Beattie; Pat B. Zanzonico; Danuta Zatorska; Tony Taldone; Stefan O. Ochiana; Mohammad M. Uddin; Eva M. Burnazi; Serge K. Lyashchenko; Clifford A. Hudis; Jacqueline Bromberg; Heiko M. Schöder; Josef J. Fox; Hanwen Zhang; Gabriela Chiosis; Jason S. Lewis; Steven M. Larson
Author Choice
A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors
Mirte Muller; Karlijn Hummelink; Daan P. Hurkmans; Anna-Larissa N. Niemeijer; Kim Monkhorst; Joanna Roder; Carlos Oliveira; Heinrich Roder; Joachim G. Aerts; Egbert F. Smit
Author Choice
A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy
Carine El Sissy; Amos Kirilovsky; Marc Van den Eynde; Ana-Maria Muşină; Maria-Gabriela Anitei; Alfredo Romero; Florence Marliot; Audelaure Junca; Jérôme Doyen; Bernhard Mlecnik; Nacilla Haicheur; Tessa Fredriksen; Christine Lagorce; Anne Jouret-Mourin; Daniel Leonard; Frédéric Bibeau; Soledad Iseas; Enrique L. Roca; Ana M. Cabanne; Carlos A. Vaccaro; Juan P. Santino; Eduardo Huertas; David Tougeron; Carlos Carvalho; Nuno Figueiredo; Rodrigo O. Perez; Angelita Habr-Gama; Viorel Scripcariu; Jean-Pierre Gerard; Jérôme Galon; Guy Zeitoun; Franck Pagès
Translational Cancer Mechanisms and Therapy
Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma
Jean-Baptiste Bachet; Hélène Blons; Pascal Hammel; Iman El Hariry; Fabienne Portales; Laurent Mineur; Jean-Philippe Metges; Claire Mulot; Camille Bourreau; Jason Cain; Jérôme Cros; Pierre Laurent-Puig
Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma
Erik Ladomersky; Lijie Zhai; Kristen L. Lauing; April Bell; Jiahui Xu; Masha Kocherginsky; Bin Zhang; Jennifer D. Wu; Joseph R. Podojil; Leonidas C. Platanias; Aaron Y. Mochizuki; Robert M. Prins; Priya Kumthekar; Jeffrey J. Raizer; Karan Dixit; Rimas V. Lukas; Craig Horbinski; Min Wei; Changyou Zhou; Graham Pawelec; Judith Campisi; Ursula Grohmann; George C. Prendergast; David H. Munn; Derek A. Wainwright
Low-Dose Hsp90 Inhibitor Selectively Radiosensitizes HNSCC and Pancreatic Xenografts
Ranjit K. Mehta; Sanjima Pal; Koushik Kondapi; Merna Sitto; Cuyler Dewar; Theresa Devasia; Matthew J. Schipper; Dafydd G. Thomas; Venkatesha Basrur; Manjunath P. Pai; Yoshihiro Morishima; Yoichi Osawa; William B. Pratt; Theodore S. Lawrence; Mukesh K. Nyati
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds